India’s Bharat Biotech ends controversial Covaxin deal with Brazilian partner Precisa

The Indian company said that despite the end of the agreement, it would continue to work with the national health regulator (ANVISA) to get the vaccine approved in Brazil.

RIO DE JANEIRO, BRAZIL - Negotiations over the health ministry's purchase of Covaxin became a target of Brazilian investigative committee Covid CPI in the Senate over suspected irregularities, prompting the Health Ministry to suspend the contract to buy the vaccine.

Indian lab Bharat Biotech, the maker of Covaxin, announced Friday, July 23, the immediate termination of the memorandum of understanding signed with Brazilian pharmaceutical company Precisa Medicamentos to commercialize the vaccine in Brazil.

In a statement, the Indian company said that despite the end of the agreement, it would continue to work with the national health regulator (ANVISA) to get . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?